Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch between originator infliximab (Remicade) and biosimilar infliximab (Remsima) in immune-mediated inflammatory diseases
2016-002061-54Phase 4Terminated
- Sponsor
- Policlinico Gemelli
- Start
- Nov 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of infliximab in rheumatoid arthritis (RA), spondyloarthritis (SpA), ankylosing spondylitis (AS) and 2 more, sponsored by Policlinico Gemelli. Primary endpoint: Serum level of anti-drug antibodies to infliximab. Started Nov 2018; status: terminated.
02
Drugs
infliximab
03
Conditions
rheumatoid arthritis (RA)spondyloarthritis (SpA)ankylosing spondylitis (AS)Crohn's diseaseautoimmune colitis
Beyond the preview
Go deeper on 2016-002061-54.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002061-54.